LifeVantage Launches Protandim, the Nrf2 Synergizer in Japan

LifeVantage Launches Protandim, the Nrf2 Synergizer in Japan

In Country Operations Formally Underway

SALT LAKE CITY, Jan. 14, 2013 (GLOBE NEWSWIRE) -- LifeVantage Corporation
(Nasdaq:LFVN), a company dedicated to helping people achieve healthy living
through a combination of a compelling business opportunity and scientifically
validated products, including its patented dietary supplement Protandim®, the
Nrf2 Synergizer®, today announced a significant milestone in its global
expansion: the Company's release of a new formulation of Protandim in Japan
with potent Nrf2 activation as well as the implementation of necessary
warehousing and product fulfillment resources to be fully operational on the
ground in Japan.

Internally directed research and development programs have enabled LifeVantage
to produce a formulation of Protandim for the Japanese market that meets
recently enacted local regulatory requirements. "As part of our ongoing Global
R&D program at LifeVantage we conducted a proprietary cell bioassay test that
allowed us to identify an ideal formula for Japan that causes significant Nrf2
activation," said LifeVantage Chief Science Officer Dr. Darlene Walley. The
formulation being distributed in Japan is the subject of a placebo controlled,
double blind clinical study being conducted at Colorado State
University.Preliminary data from that study show the product to be a potent
oxidative stress reducer.

"Today we celebrate the launch of a full-bore sales and marketing program in
Japan, a nation of 130 million," said LifeVantage President and Managing
Director Asia-Pacific David K. Toda. "We already have an established base of
independent distributors in Japan, and their enthusiasm for Protandim and
TrueScience® Anti-Aging Cream has been extraordinary."

"This is a historic day and a major milestone for LifeVantage," said President
and Chief Executive Officer Douglas C. Robinson."We could not be more pleased
with the significance of this day—moving from a NFR status to a full-business
operation in Japan. It is the culmination of two and a half years of
dedication and commitment from our corporate team, our network of independent
distributors and business partners and allows LifeVantage to realize its
mission of providing extraordinary health products to the people of Japan."

About LifeVantage Corporation

LifeVantage (Nasdaq:LFVN), a leader in Nrf2 science and the maker of
Protandim®, the Nrf2 Synergizer® patented dietary supplement, is a science
based nutraceutical company. LifeVantage is dedicated to visionary science
that looks to transform wellness and anti-aging internally and externally with
products that dramatically reduce oxidative stress at the cellular level. The
Company was founded in 2003 and is headquartered in Salt Lake City, Utah.

The LifeVantage Corporation logo is available at

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Words and expressions reflecting optimism and satisfaction with current
prospects, as well as words such as "believe," "anticipates," "look forward
to," "should" and variations thereof, identify forward-looking statements, but
their absence does not mean that a statement is not forward-looking. Examples
of forward-looking statements include, but are not limited to, statements we
make regarding our global expansion, including in Japan, and our new
formulation of Protandim for the Japanese market. Such forward-looking
statements are not guarantees of performance and the Company's actual results
could differ materially from those contained in such statements. These
forward-looking statements are based on the Company's current expectations and
beliefs concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company's actual results or
outcomes to be materially different from those anticipated and discussed
herein. These risks and uncertainties include, among others, the Company's
inability to successfully expand our operations in existing and other markets
and thereafter manage our growth; the Company's ability to retain independent
distributors or to attract new independent distributors on an ongoing basis;
the Company's ability to expand its product offerings; violations of law or
our procedures by the Company's independent distributors; the potential for
third-party and governmental actions involving the Company's network marketing
efforts; the potential for product liability claims against the Company; the
risk that government regulators and regulations could adversely affect the
Company's business; future laws or regulations may hinder or prohibit the
production or sale of the Company's existing product and any future products;
unfavorable publicity could materially hurt the Company's business; the
Company's ability to access raw materials for its Products as it grows; and
the Company's ability to protect its intellectual property rights and the
value of its product. These and other risk factors are discussed in greater
detail in the Company's Annual Report on Form 10-K and its Quarterly Report on
Form 10-Q under the caption "Risk Factors," and in other documents filed by
the Company from time to time with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the forward-looking
statements contained in this document. All forward-looking statements are
based on information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the date
of this document, except as required by law.

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC

company logo
Press spacebar to pause and continue. Press esc to stop.